MedTrace Logo

Treating Drug-Resistant Childhood Schizophrenia

NCT00048828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-07-02

No results posted yet for this study

Summary

This study will compare clozapine and olanzapine (Zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia.

Conditions

Interventions

DRUG

Olanzapine

Participants will receive olanzapine for 12 weeks.

DRUG

Clozapine

Participants will receive 12 weeks of clozapine.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Northwell Health

    lead OTHER

Principal Investigators

  • Christoph U. Correll, MD · The Zucker Hillside Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00048828 on ClinicalTrials.gov